NCT07184099

Brief Summary

This study was planned to fill the gaps regarding the effectiveness of phloroglucinol on the duration of active phase of labor.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
134

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 13, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 19, 2025

Completed
Last Updated

September 19, 2025

Status Verified

September 1, 2025

Enrollment Period

6 months

First QC Date

September 13, 2025

Last Update Submit

September 18, 2025

Conditions

Labor

Outcome Measures

Primary Outcomes (1)

  • Duration of labor

    The duration of labor was measured from the time of diagnosis of labor until full dilatation of cervix.

    4 hours

Study Arms (2)

Phloroglucinol group

EXPERIMENTAL

Phloroglucinol was administered as intravenous stat infusion with Ringer Lactate infusion.

Drug: Phloroglucinol

Placebo group

NO INTERVENTION

The patients were given only Ringer Lactate infusion.

Interventions

PhloroglucinolDRUG

Phloroglucinol was administered as intravenous stat infusion with Ringer Lactate infusion.

Phloroglucinol group

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Pregnant women aged between 18-35 years
  • Period of gestation above 37 weeks.

You may not qualify if:

  • Women with cephalopelvic disproportion
  • Double scare uterus
  • Fetal distress
  • Life threatening bleeding
  • Eclampsia
  • History of heart disease
  • Known allergy to phloroglucinol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Combined Military Hospital

Attock, Punjab Province, 43100, Pakistan

Location

MeSH Terms

Interventions

Phloroglucinol

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Tahira Riaz, FCPS

    Combined military hospital Attock

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Research Consultant

Study Record Dates

First Submitted

September 13, 2025

First Posted

September 19, 2025

Study Start

January 1, 2025

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

September 19, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Data can be shared on a reasonable request.

Locations

PA(1)